No Data
Shouxianggu: Shouxianggu 2024 Annual Results Report Announcement
Shouxianggu 2024 Annual Results Report Announcement
Zhejiang Shouxiangu Pharmaceutical (603896.SH): Net income for the fiscal year 2024 is 0.184 billion yuan, a year-on-year decrease of 27.87%.
On March 24, Glonghui reported that Zhejiang Shouxiangu Pharmaceutical (603896.SH) announced its performance report for the fiscal year 2024. During the reporting period, it achieved a revenue of 0.699 billion yuan, a year-on-year decrease of 10.87%; net income attributable to Shareholders of the listed company was 0.184 billion yuan, a year-on-year decrease of 27.87%; net income attributable to Shareholders of the listed company after deducting non-recurring gains and losses was 0.153 billion yuan, a year-on-year decrease of 32.52%. The main factors affecting operational performance are: (1) The economic recovery was not as expected, consumer confidence is insufficient, and high-end consumer demand has contracted; (2) The company's marketing reform pace has not kept up in a timely manner with the external environment.
Zhejiang Shouxiangu Pharmaceutical Completes Domestic Health Food Filing for Spore Powder Tablets
Zhejiang Shouxiangu Pharmaceutical (603896.SH): The subsidiary has completed the filing for domestically produced health food.
Gelonghui reported on March 10 that Zhejiang Shouxiangu Pharmaceutical (603896.SH) announced that its wholly-owned subsidiary, Jinhua Shouxiangu Pharmaceutical Co., Ltd., has completed the filing work for domestic health food products for the "Shouxiangu Hanfang Brand Broken Wall Ganoderma Spore Powder" and has received the domestic health food product filing certificate issued by the Zhejiang Provincial Market Supervision Administration.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s (SHSE:603896) Prospects Need A Boost To Lift Shares
